Perspective Therapeutics (CATX) 10-Q 10 May 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2019	May 08, 2019
Document Information [Line Items]
Entity Registrant Name	IsoRay, Inc.
Entity Central Index Key	0000728387
Trading Symbol	isr
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		67,338,047
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Current assets:
Cash and cash equivalents	$ 4,059	$ 2,600
Short-term investments (Note 3)	2,333	825
Accounts receivable, net	1,116	1,192
Inventory	533	494
Prepaid expenses and other current assets	390	335
Total current assets	8,431	5,446
Property and equipment, net	1,564	1,311
Restricted cash	181	181
Inventory, non-current	243	319
Other assets, net of accumulated amortization	160	198
Total assets	10,579	7,455
Current liabilities:
Accounts payable and accrued expenses	1,001	1,391
Accrued protocol expense	117	77
Accrued radioactive waste disposal	65	37
Accrued payroll and related taxes	38	155
Accrued vacation	134	175
Total current liabilities	1,355	1,835
Long-term liabilities:
Asset retirement obligation	613	590
Total liabilities	1,968	2,425
Commitments and contingencies (Note 8)
Shareholders' equity:
Preferred stock
Common stock, $.001 par value; 200,000,000 shares authorized; 67,338,047 and 56,331,147 shares issued and outstanding	67	56
Additional paid-in capital	91,941	84,322
Accumulated deficit	(83,397)	(79,348)
Total shareholders' equity	8,611	5,030
Total liabilities and shareholders' equity	10,579	7,455
Series B Preferred Stock [Member]
Shareholders' equity:
Preferred stock

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2019	Jun. 30, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	67,338,047	56,331,147
Common stock, shares outstanding (in shares)	67,338,047	56,331,147
Series B Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	59,065	59,065
Preferred stock, shares outstanding (in shares)	59,065	59,065

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Sales, net	$ 1,924	$ 1,573	$ 5,390	$ 4,320
Cost of sales	1,045	964	3,222	2,915
Gross profit	879	609	2,168	1,405
Research and development:
Proprietary research and development	299	317	1,088	914
Collaboration arrangement, net of reimbursement (Note 8)		156	45	260
Total research and development	299	473	1,133	1,174
Sales and marketing	645	692	1,996	1,980
General and administrative	1,099	783	3,173	2,610
Gain on equipment disposals	(1)		(24)
Total operating expenses	2,042	1,948	6,278	5,764
Operating loss	(1,163)	(1,339)	(4,110)	(4,359)
Non-operating income:
Interest income, net	34	7	59	17
Other income	2		2
Non-operating income, net	36	7	61	17
Net loss	(1,127)	(1,332)	(4,049)	(4,342)
Preferred stock dividends	(3)	(3)	(8)	(8)
Net loss applicable to common shareholders	$ (1,130)	$ (1,335)	$ (4,057)	$ (4,350)
Basic and diluted loss per share (in dollars per share)	$ (0.02)	$ (0.02)	$ (0.06)	$ (0.08)
Weighted average shares used in computing net loss per share:
Basic and diluted (in shares)	67,333	55,100	66,937	55,058

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,049)	$ (4,342)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation expense	100	56
Gain on equipment disposals	(24)
Amortization of other assets	37	37
Accretion of asset retirement obligation	23	22
Share-based compensation	269	317
Changes in operating assets and liabilities:
Accounts receivable, net	76	(250)
Inventory	37	(16)
Prepaid expenses and other current assets	(53)	(58)
Accounts payable and accrued expenses	(390)	96
Accrued protocol expense	40	2
Accrued radioactive waste disposal	28	(97)
Accrued payroll and related taxes	(117)	(33)
Accrued vacation	(41)	2
Net cash used by operating activities	(4,064)	(4,264)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(353)	(231)
Proceeds from sale of equipment	24
Proceeds from maturity of certificates of deposit	9,632	4,943
Purchases of and interest from certificates of deposit and U.S. Treasury Securities	(11,141)	(4,054)
Net cash (used) provided by investing activities	(1,838)	658
CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid	(11)	(11)
Proceeds from sales of common stock, pursuant to registered direct offering, net	7,370
Proceeds from sales of common stock, pursuant to exercise of options	2	50
Net cash provided by financing activities	7,361	39
Net increase (decrease) in cash, cash equivalents, and restricted cash	1,459	(3,567)
Cash, cash equivalents, and restricted cash beginning of period	2,781	6,113
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF PERIOD	4,240	2,546
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	4,059	2,365
Restricted cash	181	181
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF PERIOD	4,240	2,546
Non-cash investing and financing activities:
Warrants issued to placement agent of registered direct offering	$ 163

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Jun. 30, 2017	59,065	55,017,419
Balances at Jun. 30, 2017		$ 55		$ 83,151	$ (72,604)	$ 10,602
Share-based compensation				90		90
Net loss					(1,546)	(1,546)
Balances (in shares) at Sep. 30, 2017	59,065	55,017,419
Balances at Sep. 30, 2017		$ 55		83,241	(74,150)	9,146
Balances (in shares) at Jun. 30, 2017	59,065	55,017,419
Balances at Jun. 30, 2017		$ 55		83,151	(72,604)	10,602
Net loss						$ (4,342)
Issuance of common stock pursuant to exercise of options (in shares)						82,810
Balances (in shares) at Mar. 31, 2018	59,065	55,100,229
Balances at Mar. 31, 2018		$ 55		83,507	(76,946)	$ 6,616
Balances (in shares) at Sep. 30, 2017	59,065	55,017,419
Balances at Sep. 30, 2017		$ 55		83,241	(74,150)	9,146
Share-based compensation				78		78
Net loss					(1,464)	(1,464)
Payment of dividend to preferred shareholders				(11)		(11)
Issuance of common stock pursuant to exercise of options (in shares)		82,810
Issuance of common stock pursuant to exercise of options				50		50
Share-based compensation for third party services				72		72
Balances (in shares) at Dec. 31, 2017	59,065	55,100,229
Balances at Dec. 31, 2017		$ 55		83,430	(75,614)	7,871
Share-based compensation				77		77
Net loss					(1,332)	$ (1,332)
Issuance of common stock pursuant to exercise of options (in shares)						0
Balances (in shares) at Mar. 31, 2018	59,065	55,100,229
Balances at Mar. 31, 2018		$ 55		83,507	(76,946)	$ 6,616
Balances (in shares) at Jun. 30, 2018	59,065	56,331,147
Balances at Jun. 30, 2018		$ 56		84,322	(79,348)	5,030
Issuance of common stock pursuant to registered direct offering, net (in shares)		11,000,000
Issuance of common stock pursuant to registered direct offering, net		$ 11		7,483		7,494
Share-based compensation				93		93
Net loss					(1,508)	(1,508)
Balances (in shares) at Sep. 30, 2018	59,065	67,331,147
Balances at Sep. 30, 2018		$ 67		91,898	(80,856)	11,109
Balances (in shares) at Jun. 30, 2018	59,065	56,331,147
Balances at Jun. 30, 2018		$ 56		84,322	(79,348)	5,030
Net loss						$ (4,049)
Issuance of common stock pursuant to exercise of options (in shares)						6,900
Balances (in shares) at Mar. 31, 2019	59,065	67,338,047
Balances at Mar. 31, 2019		$ 67		91,941	(83,397)	$ 8,611
Balances (in shares) at Sep. 30, 2018	59,065	67,331,147
Balances at Sep. 30, 2018		$ 67		91,898	(80,856)	11,109
Share-based compensation				97		97
Net loss					(1,414)	(1,414)
Offering costs pursuant to registered direct offering, net				(116)		(116)
Payment of dividend to preferred shareholders				(11)		(11)
Balances (in shares) at Dec. 31, 2018	59,065	67,331,147
Balances at Dec. 31, 2018		$ 67		91,868	(82,270)	9,665
Share-based compensation				79		79
Net loss					(1,127)	(1,127)
Offering costs pursuant to registered direct offering, net				(8)		$ (8)
Issuance of common stock pursuant to exercise of options (in shares)		6,900				6,900
Issuance of common stock pursuant to exercise of options				2		$ 2
Balances (in shares) at Mar. 31, 2019	59,065	67,338,047
Balances at Mar. 31, 2019		$ 67		$ 91,941	$ (83,397)	$ 8,611

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Basis of Presentation The accompanying unaudited interim consolidated financial statements are those of Isoray, Inc., and its wholly-owned subsidiaries referred to herein as “Isoray” or the “Company”. All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form 10 June 30, 2018. The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not Certain prior period amounts have been reclassified to conform to the current period’s presentation. The results of operations for the periods presented may not may 2019 0%.

Note 2 - New Accounting Pronoun

Note 2 - New Accounting Pronouncements	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	2. New Accounting Pronouncements In May 2014, No. 2014 09 605 10 five first 2019. first 2019 2014 09 not not In February 2016, 2016 02 842 December 15, 2018, first 2020. In August 2016, No. 2016 15 230 eight December 15, 2017, 2016 15 July 1, 2018. 2016 15 not In November 2016, 2016 18, 230 2016 18 no one 2016 18 December 15, 2017 2016 18 first 2019. $181,000 first In November 2018, 2018 18, 808 808 606, 606. December 15, 2019, In August 2018, No. 33 10532, March 31, 2019. Other accounting standards that have been issued or proposed by FASB that do not not not not

Note 3 - Short-Term Investments

Note 3 - Short-Term Investments	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Cost-method Investments, Description [Text Block]	3. Short-Term Investments The Company had short-term investments consisting of U.S. Treasury Securities and Certificate of Deposit Account Registry Service (CDARS) as of March 31, 2019 June 30, 2018 Certificate of Deposit Account Registry Service (CDARS) is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the $250,000 Short-term investments held by the Company as of March 31, 2019 June 30, 2018 As of March 31, 2019 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year U.S. Treasury Securities $ 2,333 $ - $ - $ - As of June 30, 2018 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 825 $ - $ - $ -

Note 4 - Loss Per Share

Note 4 - Loss Per Share	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Loss per Share Basic and diluted earnings (loss) per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding and does not March 31, 2019 2018, not Securities not March 31, 2019 2018, March 31, 2019 2018 Series B preferred stock 59 59 Common stock warrants 6,080 250 Common stock options 3,925 3,272 Total potential dilutive securities 10,064 3,581

Note 5 - Inventory

Note 5 - Inventory	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventory Inventory consisted of the following at March 31, 2019 June 30, 2018 ( March 31, June 30, 2019 2018 Raw materials $ 383 $ 371 Work in process 114 96 Finished goods 36 27 Total inventory, current $ 533 $ 494 March 31, June 30, 2019 2018 Enriched barium, non-current $ 193 $ 276 Raw materials, non-current 50 43 Total inventory, non-current $ 243 $ 319 Inventory, non-current is raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will not August 25, 2017, 130 131 4,000 131. March 31, 2019, 1,678 303 12 1,375 12 no third 131

Note 6 - Property and Equipment

Note 6 - Property and Equipment	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and Equipment Property and equipment consisted of the following at March 31, 2019 June 30, 2018 ( March 31, June 30, 2019 2018 Land $ 366 $ 366 Equipment 3,802 4,152 Leasehold improvements 4,143 4,136 Other 1 587 328 Property and equipment 8,898 8,982 Less accumulated depreciation (7,334 ) (7,671 ) Property and equipment, net $ 1,564 $ 1,311 1. Plant and equipment, not no March 31, 2019 June 30, 2018 $207,000

Note 7 - Share-Based Compensati

Note 7 - Share-Based Compensation	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	7. Share-Based Compensation The following table presents the share-based compensation expense recognized for stock-based options during the three March 31, 2019 2018 Three Months 2019 2018 Cost of sales $ 9 $ 10 Research and development expenses 18 20 Sales and marketing expenses 22 17 General and administrative expenses 30 30 Total share-based compensation $ 79 $ 77 The following table presents the share-based compensation expense recognized for stock-based options during the nine March 31, 2019 2018 Nine Months 2019 2018 Cost of sales $ 30 $ 40 Research and development expenses 54 58 Sales and marketing expenses 65 50 General and administrative expenses 120 97 Total share-based compensation $ 269 $ 245 As of March 31, 2019, $494,000 .95 During the nine March 31, 2018, $72,000 A summary of stock options within the Company’s share-based compensation plans as of March 31, 2019 Weighted Weighted Average Number of Exercise Contractual Intrinsic As of March 31, 2019 Options Price Term (Years) Value Outstanding 3,925 $ .67 7.18 $ 10 Vested and expected to vest 3,925 $ .67 7.18 $ 10 Vested and exercisable 2,163 $ .79 5.85 $ 10 There were 6,900 no $1,000 $0 three March 31, 2019 2018, There were 25,000 15,000 $7,000 $5,000 three March 31, 2019 2018, There were 10,000 no three March 31, 2019 2018, There were no 37,500 three March 31, 2019 2018, There were 6,900 82,810 $1,000 $0 nine March 31, 2019 2018, There were 262,500 90,000 $94,000 $38,000 nine March 31, 2019 2018, There were 20,000 no nine March 31, 2019 2018, There were 70,750 114,041 nine March 31, 2019 2018,

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Isotope Purchase Agreement In December 2015, 131 one 131. March 31, 2017, December 2016 December 31, 2017. October 23, 2017, 131 December 31, 2018. December 24, 2018, December 31, 2019 131. 131 May 31, 2019. Research and Development - Collaborative Arrangement On March 13, 2017, November 8, 2016, March 2018 not March 2018, 510 no three nine March 31, 2019, 50% December 2018. not not three March 31, 2019, not During the three March 31, 2019 2018, $31,000 $304,000, During the nine March 31, 2019 2018, $235,000 $509,000, As of March 31, 2019 June 30, 2018, $30,000 $22,000

Note 9 - Fair Value Measurement

Note 9 - Fair Value Measurements	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	9. Fair Value Measurements The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement (in thousands): Fair Value at March 31, 2019 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 4,059 $ 4,059 $ - $ - Fair Value at June 30, 2018 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 2,600 $ 2,600 $ - $ - The Company’s cash and cash equivalent instruments are classified within Level 1

Note 10 - Concentrations of Cre

Note 10 - Concentrations of Credit and Other Risks	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	10. Concentrations of Credit and Other Risks One group of customers, facilities or physician practices has revenues that aggregate to greater than 10% Nine months ended March 31, March 31, Facility 2019 2018 El Camino Hospital of Los Gatos & other facilities 1 20.97 % 24.23 % 1 10% one The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary.

Note 11 - Shareholders' Equity

Note 11 - Shareholders' Equity	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Shareholders’ Equity On July 11, 2018, 11,000,000 $0.75, $8.25 $0.75 In a concurrent private placement, the Company sold to each Investor, at no 50% 5,500,000 $0.75 January 11, 2019 January 11, 2024 ( 330,000 $0.9375, The aggregate number of shares of our common stock issuable upon the exercise of the Warrants is 5,830,000 In connection with redomiciling the Company to Delaware, Preferred Stock Series A, C and D designations were terminated. There were no March 31, 2019 59,065 March 31, 2019.

Note 12 - Contracts With Custom

Note 12 - Contracts With Customers	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	12. Contracts with Customers We have adopted ASC 606, Revenue from Contracts with Customers July 1, 2018 not July 1, 2018 . five 2019 606, not 605, Revenue Recognition We routinely enter into agreements with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products that we offer. However, these agreements do not no not not not not not Revenues for all products are typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no Sources of Revenue We have identified the following revenues disaggregated by revenue source: 1. Domestic – direct sales of products and services. 2. International – direct sales of products and services. For the three March 31, 2019 2018 no nine March 31, 2019 2018 three March 31, 2019, 88% 12% 83% 17%, three March 31, 2018. nine March 31, 2019, 88% 12% 86% 14%, nine March 31, 2018. Contract Balances We incur agreement obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate. Warranty Our general product warranties do not not Returns Generally, we allow returns if not Significant Judgments in the Application of the Guidance in ASC 606 There are no Commissions and Contract Costs We pay and expense commissions on orders to our sales team upon satisfaction of our performance obligations. We generally do not Practical Expedients Our payment terms for sales direct to customers and distributors are substantially less than the one Shipping and Handling Charges Fees charged to customers for shipping and handling of products are included as revenue and the costs for shipping and handling of products are included as a component of cost of products. Taxes Collected from Customers As our products are used in another service and are exempt, to this point we have not Effective Date and Transition Disclosures Adoption of the new standard related to revenue recognition did not not

Note 3 - Short-Term Investmen_2

Note 3 - Short-Term Investments (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Cost Method Investments [Table Text Block]	As of March 31, 2019 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year U.S. Treasury Securities $ 2,333 $ - $ - $ - As of June 30, 2018 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 825 $ - $ - $ -

Note 4 - Loss Per Share (Tables

Note 4 - Loss Per Share (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	March 31, 2019 2018 Series B preferred stock 59 59 Common stock warrants 6,080 250 Common stock options 3,925 3,272 Total potential dilutive securities 10,064 3,581

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, June 30, 2019 2018 Raw materials $ 383 $ 371 Work in process 114 96 Finished goods 36 27 Total inventory, current $ 533 $ 494
Schedule of Inventory, Noncurrent [Table Text Block]	March 31, June 30, 2019 2018 Enriched barium, non-current $ 193 $ 276 Raw materials, non-current 50 43 Total inventory, non-current $ 243 $ 319

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, June 30, 2019 2018 Land $ 366 $ 366 Equipment 3,802 4,152 Leasehold improvements 4,143 4,136 Other 1 587 328 Property and equipment 8,898 8,982 Less accumulated depreciation (7,334 ) (7,671 ) Property and equipment, net $ 1,564 $ 1,311

Note 7 - Share-Based Compensa_2

Note 7 - Share-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months 2019 2018 Cost of sales $ 9 $ 10 Research and development expenses 18 20 Sales and marketing expenses 22 17 General and administrative expenses 30 30 Total share-based compensation $ 79 $ 77 Nine Months 2019 2018 Cost of sales $ 30 $ 40 Research and development expenses 54 58 Sales and marketing expenses 65 50 General and administrative expenses 120 97 Total share-based compensation $ 269 $ 245
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Weighted Weighted Average Number of Exercise Contractual Intrinsic As of March 31, 2019 Options Price Term (Years) Value Outstanding 3,925 $ .67 7.18 $ 10 Vested and expected to vest 3,925 $ .67 7.18 $ 10 Vested and exercisable 2,163 $ .79 5.85 $ 10

Note 9 - Fair Value Measureme_2

Note 9 - Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value at March 31, 2019 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 4,059 $ 4,059 $ - $ - Fair Value at June 30, 2018 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 2,600 $ 2,600 $ - $ -

Note 10 - Concentrations of C_2

Note 10 - Concentrations of Credit and Other Risks (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Nine months ended March 31, March 31, Facility 2019 2018 El Camino Hospital of Los Gatos & other facilities 1 20.97 % 24.23 %

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation (Details Textual)	9 Months Ended
	Mar. 31, 2019
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%

Note 2 - New Accounting Prono_2

Note 2 - New Accounting Pronouncements (Details Textual) - USD ($)	Mar. 31, 2019	Jul. 01, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance	$ 4,240,000		$ 2,781,000	$ 2,546,000	$ 6,113,000
Accounting Standards Update 2016-18 [Member]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance		$ 181,000

Note 3 - Short-Term Investmen_3

Note 3 - Short-Term Investments - Summary of Short- Term Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Short-term investments (Note 3)	$ 2,333	$ 825
Under 90 Days [Member] | US Treasury and Government Short-term Debt Securities [Member]
Short-term investments (Note 3)	2,333
Under 90 Days [Member] | Certificates of Deposit [Member]
Short-term investments (Note 3)		825
For 91 Days to Six Months [Member] | US Treasury and Government Short-term Debt Securities [Member]
Short-term investments (Note 3)
For 91 Days to Six Months [Member] | Certificates of Deposit [Member]
Short-term investments (Note 3)
Six Months to 1 Year [Member] | US Treasury and Government Short-term Debt Securities [Member]
Short-term investments (Note 3)
Six Months to 1 Year [Member] | Certificates of Deposit [Member]
Short-term investments (Note 3)
Greater than 1 Year [Member] | US Treasury and Government Short-term Debt Securities [Member]
Short-term investments (Note 3)
Greater than 1 Year [Member] | Certificates of Deposit [Member]
Short-term investments (Note 3)

Note 4 - Loss Per Share - Antid

Note 4 - Loss Per Share - Antidilutive Securities (Details) - shares shares in Thousands	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive securities (in shares)	10,064	3,581
Series B Preferred Stock [Member]
Antidilutive securities (in shares)	59	59
Warrant [Member]
Antidilutive securities (in shares)	6,080	250
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	3,925	3,272

Note 5 - Inventory - Current In

Note 5 - Inventory - Current Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Raw materials	$ 383	$ 371
Work in process	114	96
Finished goods	36	27
Total inventory, current	$ 533	$ 494

Note 5 - Inventory - Noncurrent

Note 5 - Inventory - Noncurrent Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Total inventory, non-current	$ 243	$ 319
Enriched Barium Inventory [Member]
Total inventory, non-current	193	276
Raw Materials [Member]
Total inventory, non-current	$ 50	$ 43

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($)	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018
Depreciation, Total	$ 100,000	$ 56,000
Other [Member]
Depreciation, Total	0
Construction in Progress [Member]
Capitalized Costs Related to Advance Planning and Design Work	$ 207,000		$ 207,000

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands		Mar. 31, 2019	Jun. 30, 2018
Property and equipment, gross		$ 8,898	$ 8,982
Less accumulated depreciation		(7,334)	(7,671)
Property and equipment, net		1,564	1,311
Land [Member]
Property and equipment, gross		366	366
Equipment [Member]
Property and equipment, gross		3,802	4,152
Leasehold Improvements [Member]
Property and equipment, gross		4,143	4,136
Other [Member]
Property and equipment, gross	[1]	$ 587	$ 328
[1]	Plant and equipment, not placed in service are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore, no depreciation expense has been recognized. Also included at March 31, 2019 and June 30, 2018 are costs associated with advance planning and design work on the Company's new production facility of $207,000.

Note 7 - Share-Based Compensa_3

Note 7 - Share-Based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 494,000		$ 494,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			346 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	6,900	0	6,900	82,810
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 1,000	$ 0	$ 1,000	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	25,000	15,000	262,500	90,000
Share-based Compensation Arrangement By Share-based Payment Award Options Grants in Period Fair Value	$ 7,000	$ 5,000	$ 94,000	$ 38,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	10,000	0	20,000	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	0	37,500	70,750	114,041
Al & J Media [Member]
Issuance of Stock and Warrants for Services or Claims				$ 72,000

Note 7 - Share-Based Compensa_4

Note 7 - Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Share-based compensation	$ 79	$ 77	$ 269	$ 245
Cost of Sales [Member]
Share-based compensation	9	10	30	40
Research and Development Expense [Member]
Share-based compensation	18	20	54	58
Selling and Marketing Expense [Member]
Share-based compensation	22	17	65	50
General and Administrative Expense [Member]
Share-based compensation	$ 30	$ 30	$ 120	$ 97

Note 7 - Share-Based Compensa_5

Note 7 - Share-Based Compensation - Summary of Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Outstanding (in shares) | shares	3,925
Outstanding, weighted exercise price (in dollars per share) | $ / shares	$ 0.67
Outstanding, weighted average contractual term (Year)	7 years 65 days
Outstanding, intrinsic value | $	$ 10
Vested and expected to vest, Options (in shares) | shares	3,925
Vested and expected to vest, weighted exercise price (in dollars per share) | $ / shares	$ 0.67	[1]
Vested and expected to vest, weighted average contractual term (Year)	7 years 65 days	[2]
Vested and expected to vest, intrinsic value | $	$ 10	[3]
Vested and exercisable (in shares) | shares	2,163
Vested and exercisable, weighted exercise price (in dollars per share) | $ / shares	$ 0.79
Vested and exercisable, weighted average contractual term (Year)	5 years 310 days
Vested and exercisable, intrinsic value | $	$ 10
[1]	Weighted average exercise price per share.
[2]	Weighted average remaining contractual life.
[3]	Aggregate intrinsic value (in thousands).

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018
Purchase Agreement Period	1 year
Research and Development Expense, Total		$ 299,000	$ 473,000	$ 1,133,000	$ 1,174,000
Receivables, Net, Current, Total		1,116,000		1,116,000		$ 1,192,000
Collaborative Development Agreement [Member]
Research and Development Expense, Total		31,000	$ 304,000	235,000	$ 509,000
Collaborative Development Agreement [Member] | GammaTile LLC [Member]
Receivables, Net, Current, Total		$ 30,000		$ 30,000		$ 22,000

Note 9 - Fair Value Measureme_3

Note 9 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Cash and cash equivalents	$ 4,059	$ 2,600
Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	4,059	2,600
Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents
Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents

Note 10 - Concentrations of C_3

Note 10 - Concentrations of Credit and Other Risks - Revenue Concentration (Details)		9 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Revenue from Contract with Customer, Product and Service Benchmark [Member] | Company Sales [Member]
El Camino Hospital of Los Gatos & other facilities 1	[1]	20.97%	24.23%
[1]	This group of facilities individually each comprise less than 10% of total Company sales. They are serviced by the same physician group, one of whom is our Medical Director.

Note 11 - Shareholders' Equity

Note 11 - Shareholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jul. 11, 2018	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018
Proceeds from Issuance of Common Stock		$ 7,370
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,830,000
Series A Preferred Stock [Member]
Preferred Stock, Shares Issued, Total		0
Series B Preferred Stock [Member]
Preferred Stock, Shares Issued, Total		59,065		59,065
Preferred Stock, Shares Outstanding, Ending Balance		59,065		59,065
Series C Preferred Stock [Member]
Preferred Stock, Shares Issued, Total		0
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued, Total		0
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	11,000,000
Shares Issued, Price Per Share	$ 0.75
Proceeds from Issuance of Common Stock	$ 8,250
Payments of Stock Issuance Costs	$ 750
Class of Warrant Or Right, Authorized, Percentage	50.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Private Placement [Member] | H.C. Wainwright & Co., LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	330,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.9375

Note 12 - Contracts With Cust_2

Note 12 - Contracts With Customers (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Prostate Brachytherapy [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage	88.00%	83.00%	88.00%	86.00%
Product and Service, Other [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage	12.00%	17.00%	12.00%	14.00%
Geographic Distribution, Foreign [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total	$ 0	$ 0